Synthesis of 1,4-azaphosphinine nucleosides and evaluation as inhibitors of human cytidine deaminase and APOBEC3A
Open Access
- 15 May 2024
- journal article
- research article
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 20 (1) , 1088-1098
Abstract
Nucleoside and polynucleotide cytidine deaminases (CDAs), such as CDA and APOBEC3, share a similar mechanism of cytosine to uracil conversion. In 1984, phosphapyrimidine riboside was characterised as the most potent inhibitor of human CDA, but the quick degradation in water limited the applicability as a potential therapeutic. To improve stability in water, we synthesised derivatives of phosphapyrimidine nucleoside having a CH2 group instead of the N3 atom in the nucleobase. A charge-neutral phosphinamide and a negatively charged phosphinic acid derivative had excellent stability in water at pH 7.4, but only the charge-neutral compound inhibited human CDA, similar to previously described 2'-deoxyzebularine (Ki = 8.0 ± 1.9 and 10.7 ± 0.5 µM, respectively). However, under basic conditions, the charge-neutral phosphinamide was unstable, which prevented the incorporation into DNA using conventional DNA chemistry. In contrast, the negatively charged phosphinic acid derivative was incorporated into DNA instead of the target 2'-deoxycytidine using an automated DNA synthesiser, but no inhibition of APOBEC3A was observed for modified DNAs. Although this shows that the negative charge is poorly accommodated in the active site of CDA and APOBEC3, the synthetic route reported here provides opportunities for the synthesis of other derivatives of phosphapyrimidine riboside for potential development of more potent CDA and APOBEC3 inhibitors.Keywords
All Related Versions
Funding Information
- Breast Cancer Foundation New Zealand (HRC 20/1355)
- Maurice Wilkins Centre for Molecular Biodiscovery
- Breast Cancer Cure (HRC 20/1355)
- Palmerston North Medical Research Foundation
- Health Research Council of New Zealand (20/1355)
- Kiwi Innovation Network (MU002391)
- Massey Ventures Ltd (MU002391)
- Worldwide Cancer Research (16–1197)
- Massey University (RM20734)
This publication has 76 references indexed in Scilit:
- Differential Inhibition of APOBEC3 DNA‐Mutator Isozymes by Fluoro‐ and Non‐Fluoro‐Substituted 2′‐Deoxyzebularine Embedded in Single‐Stranded DNAChemBioChem, 2019
- Global Regression Using the Explicit Solution of Michaelis‐Menten Kinetics Employing Lambert's W Function: High Robustness of Parameter EstimatesChemistrySelect, 2019
- APOBEC Enzymes as Targets for Virus and Cancer TherapyCell Chemical Biology, 2018
- Efficient and Controllable Esterification of P(O)‐OH Compounds Using Uronium‐Based SaltsChemistrySelect, 2017
- Mycoplasma hyorhinis‐encoded cytidine deaminase efficiently inactivates cytosine‐based anticancer drugsFEBS Open Bio, 2015
- Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast CancersDiscover Oncology, 2014
- Bis(trimethylsiloxy)phosphine2013
- Recombinant Human Cytidine Deaminase: Expression, Purification, and CharacterizationProtein Expression and Purification, 1996
- Cytidine Deaminase. The 2·3 Å Crystal Structure of an Enzyme: Transition-state Analog ComplexJournal of Molecular Biology, 1994
- Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compoundsBiochemical Pharmacology, 1980